MedTrace Logo

Dietary Supplement for Myopia Control

NCT07406906 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 156

Last updated 2026-07-24

No results posted yet for this study

Summary

The purpose of this clinical trial is to investigate the changes in choroidal thickness and vasculature in myopic children following oral supplementation.

Conditions

  • Myopia

Interventions

DIETARY_SUPPLEMENT

Oral dietary supplement provided in a capsule format (3 active capsules/ per day)

The active intervention in this study is an oral dietary supplement provided in a capsule format. The active ingredients include DHA/EPA and Astaxanthin.

DIETARY_SUPPLEMENT

Oral dietary supplement provided in a capsule format (1 active capsule and 2 placebo capsules/per day)

The active intervention in this study is an oral dietary supplement provided in a capsule format. The active ingredients include DHA/EPA and Astaxanthin.

OTHER

Placebo control (3 placebo capsules/per day)

3 placebo capsules/per day

Sponsors & Collaborators

  • The Hong Kong Polytechnic University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
8 Years
Max Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-01
Primary Completion
2026-12-30
Completion
2026-12-30

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07406906 on ClinicalTrials.gov